Upanib 15 mg (Upadacitinib) Tablets
Introduction to Upanib 15 mg (Upadacitinib): Upanib 15 mg, containing the active ingredient Upadacitinib, is a potent medication manufactured by Ziska Pharmaceuticals Ltd. It belongs to the class of Janus kinase (JAK) inhibitors and is primarily used in the treatment of various inflammatory conditions, including rheumatoid arthritis and psoriatic arthritis. While not directly indicated for […]
Vescap 1g (Icosapent Ethyl) Capsules
Introduction of Vescap 1g: Vescap 1g, crafted by Ziska Pharmaceuticals Limited, stands as a beacon of progress in cardiovascular medicine, particularly in managing hypertriglyceridemia. As a global leader in oncology-based product supply, Onco Solution ensures the global distribution of Vescap 1g, enabling access for patients worldwide. This comprehensive description explores the mechanism, usage, benefits, and […]
Lornatib 100 MG (Lorlatinib) Tablets
Introduction to Lornatib 100 MG: Pioneering Precision Therapy for ALK-Positive Cancers Lornatib 100 mg, crafted by Ziska Pharmaceuticals Limited, emerges as a beacon of hope in the realm of oncology. With Lorlatinib as its cornerstone, this medication offers a targeted approach to combating ALK-positive cancers, revolutionizing treatment paradigms. Supported by Onco Solution, a premier global […]
Mobonib 40 MG (Mobocertinib) Capsules
Introduction to Mobonib 40 MG: Pioneering Precision Treatment for EGFR-Mutated Cancers Mobonib 40 , developed by Ziska Pharmaceuticals Limited, represents a breakthrough in managing EGFR-mutated cancers. With Mobocertinib as its active ingredient, this medication offers a targeted therapeutic approach tailored to the specific molecular characteristics of these malignancies. Supported by Onco Solution, a leading global […]
Olakin 150 MG (Olaparib) Tablets
Introduction to Olakin 150 mg Olakin 150 mg, innovatively crafted by Ziska Pharmaceuticals Limited and featuring the active ingredient Olaparib, is at the forefront of precision medicine in cancer therapy. This groundbreaking medication specifically targets genetic mutations, offering renewed hope and significantly improved treatment outcomes for patients battling certain cancer types. Through the meticulous development […]
Osikin 80 MG (Osimertinib) Tablets
Introduction to Osikin 80 MG: Osikin 80 marks a significant milestone in the realm of cancer therapeutics, particularly in the treatment of non-small cell lung cancer (NSCLC) harboring specific EGFR mutations. Manufactured by Ziska Pharmaceuticals Limited, this medication encapsulates Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Osimertinib boasts exceptional efficacy […]
Ruxonib cream (ruxolitinib)
Introduction of Ruxonib Cream: Ruxonib Cream, infused with Ruxolitinib and crafted by Ziska Pharmaceuticals Limited, marks a significant leap in dermatologic therapy. As a targeted solution for inflammatory skin diseases, this cream introduces a new era of relief and enhanced life quality for patients with psoriasis and atopic dermatitis. Onco Solution, a global distributor and […]
Sotakras 120 MG (Sotorasib) Tablets
Revolutionizing Targeted Therapy with Sotakras 120 MG: Sotakras 120 mg is at the forefront of targeted cancer therapy, embodying a groundbreaking approach to combating oncological diseases. Its active ingredient, Sotorasib, is specifically designed to selectively inhibit KRAS G12C, a mutation found in a variety of cancers, including non-small cell lung cancer (NSCLC). By focusing on […]
Tractoni 100 MG (Larotrectinib) Capsules
Introduction to Tractoni 100 mg Tractoni 100 mg, containing larotrectinib and manufactured by Ziska Pharmaceuticals Limited, signifies a paradigm shift in oncology treatment. This medication offers targeted therapy for patients with specific gene fusions, providing hope and improved outcomes in their cancer journey. Description and Usage of Tractoni 100 mg Tractoni 100 mg features Larotrectinib, […]
Trombola 50 MG (Eltrombopag Olamine) Tablets
Introduction to Trombola 50 mg Trombola 50 mg, a pharmaceutical breakthrough manufactured by Ziska Pharmaceuticals Limited, represents a beacon of hope for individuals grappling with thrombocytopenia. This medication provides a vital therapeutic avenue for managing low platelet counts, offering patients a pathway to enhanced quality of life and reduced risk of bleeding complications. Description and […]
Tukanic 150 MG (Tucatinib) Tablets
Introduction of Tukanic 150 mg Tukanic 150, featuring Tucatinib as its active ingredient, represents a pivotal advancement in the treatment paradigm for HER2-positive breast cancer. Developed by Ziska Pharmaceuticals Limited, this innovative medication offers new avenues for managing this aggressive form of breast cancer, providing patients with enhanced therapeutic options and improved outcomes. In collaboration […]
Cabani 200 MG (Capmatinib) Tablets
Introduction to Cabani 200 MG: A New Era of Precision Medicine Manufactured by Ziska Pharmaceuticals Limited, Cabani 200 signifies a paradigm shift towards precision medicine tailored to the molecular characteristics of individual tumors. With Capmatinib as its active ingredient, this medication targets and inhibits the MET receptor tyrosine kinase, a crucial protein involved in the […]
Caboxib 20 MG (Cabozantinib) Capsules
Caboxib 20 MG: Transforming Precision Oncology In the landscape of oncology-based healthcare, Ziska Pharmaceuticals Limited introduces Caboxib 20 , a groundbreaking medication poised to redefine the treatment paradigm for certain types of cancer. Collaborating with Onco Solution, the global medicine supplier and information provider, Caboxib 20 emerges as a beacon of hope, offering precision-targeted therapy […]
Caboxib 80 MG (Cabozantinib) Capsules
Caboxib 80 MG: Advancing Precision Oncology In the realm of oncology-based healthcare, Ziska Pharmaceuticals Limited presents Caboxib 80 mg, a pioneering medication set to redefine the treatment landscape for various malignancies. Collaborating with Onco Solution, a global medicine supplier and information provider, Caboxib 80 mg emerges as a beacon of hope, offering precision-targeted therapy to […]
Crizona 250 MG (Crizotinib) Capsules
Crizona 250 MG: Advancing Precision Oncology In the realm of oncology-based healthcare, Crizona 250 mg, developed by Ziska Pharmaceuticals Limited, stands as a hallmark of precision medicine. With its formulation containing Crizotinib, this innovative medication targets specific genetic abnormalities driving cancer cell growth and spread, ushering in a new era of personalized cancer treatment. Supported […]
Deucrava 6 mg (Deucravacitinib) Tablets
Exploring the Therapeutic Landscape: Deucrava 6 MG Deucravacitinib in Oncology Care In the vast landscape of oncology care, where each patient’s journey is unique, Deucrava 6 mg emerges as a beacon of hope, offering targeted therapy for individuals facing challenging diagnoses. Manufactured by Ziska Pharmaceuticals Limited, Deucrava 6 represents a culmination of scientific innovation and […]
Enacitib 50 MG (Enasidenib) Tablets
Exploring the Therapeutic Landscape: Enacitib 50 MG (Enasidenib) in Precision Oncology In the vast and evolving landscape of oncology care, each patient’s journey is unique, presenting clinicians with the challenge of identifying tailored treatment approaches that address the specific molecular drivers of their disease. Enacitib 50 , manufactured by Ziska Pharmaceuticals Limited, emerges as a […]
Enacitib 100 MG (Enasidenib) Tablets
Enacitib 100 MG: Revolutionizing Cancer Treatment Enacitib 100 mg, manufactured by Ziska Pharmaceuticals Limited, stands as a beacon of hope in the landscape of precision oncology. As a targeted therapy specifically designed for hematologic malignancies driven by IDH2 mutations, Enacitib 100 mg represents a transformative advancement in cancer treatment. Supported by Onco Solution, a global […]
Abiron 250 mg (Abiraterone Acetate) Tablets
Introduction: Abiron 250 mg, comprising Abiraterone Acetate and manufactured by Ziska Pharmaceuticals Limited, emerges as a cornerstone in the treatment of advanced prostate cancer. This medication offers a novel therapeutic approach by inhibiting androgen production, thereby slowing cancer progression and improving patients’ quality of life. Description and Usage: Abiron 250 contains Abiraterone Acetate, an orally […]
Avatropag 20 mg (Avatrombopag) Tablets
Introduction: Avatropag 20 mg, developed by Ziska Pharmaceuticals Limited and distributed globally by Onco Solution, stands at the forefront of thrombocytopenia management in cancer patients. With its innovative approach and collaborative efforts, Avatropag 20 offers a ray of hope, enhancing patient outcomes and quality of life amidst the challenges of cancer treatment. Introduction to Avatropag […]
